Ergoteles LLC Adverum Biotechnologies, Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $154,539 - $2.95 Million	-286,185 Reduced 77.62%	82,499 $47,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $49,071 - $494,802	-51,116 Reduced 12.18%	368,684 $350,000
Q2 2022 Aug 12, 2022	BUY	$0.81 - $1.34 $340,038 - $562,532	419,800 New	419,800 $504,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $105,270 - $145,200	-60,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $48,464 - $83,880	23,300 Added 62.63%	60,500 $131,000
Q2 2021 Aug 12, 2021	BUY	$3.36 - $10.56 $124,992 - $392,832	37,200 New	37,200 $130,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.